

STENOCARE A/S

NASDAQ FIRST NORTH GROWTH MARKET, DENMARK

TICKER: STENO

Interim Report fourth Quarter and full year 2020

STENOCARE A/S (“STENOCARE”) today announces its unaudited results for the period 01.01.2020 – 31.12.2020. The report is attached to this release and is also available on <https://stenocare.com/investor-relations/>

Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:

“Despite the continued challenges caused by Covid19 STENOCARE was able to return to having medical cannabis products for sale in Sweden in the fourth quarter of 2020. This was important for several reasons: We entered a new country, started generating revenue and it was proof of our ability to execute on the STENOCARE 2.0 strategy”.

(DKKK)	01.10.2020	01.10.2019	01.01.2020	01.01.2019
	31.12.2020	31.12.2019	31.12.2020	31.12.2019
	3 months	3 months	12 months	12 months
Total income *)	105	11,255	198	16,206
Net sales	105	0	198	4,942
Operating profit before depreciation (EBITDA)	-3,845	7,313	-11,831	4,417
Net financial items	-11	-485	-1,648	-2,112
Result per share (DKK)	-0.34	0.59	-1.12	0.19
Solidity (%)	93	43	93	43

Result per share: The result for the period divided by the average number of shares. Total number of shares as of December 31, 2020, amounted to 11,676,126 (8,942,762). Average number of shares for the fourth quarter 2020 was 11,676,126 (8,942,762).

Solidity: Equity divided by total capital.

*Total income includes net sales and other income.

Highlights during the period

- December 2020, STENOCARE announced the first delivery of THC medical cannabis oil products to Swedish patients
- December 2020, the company shared the decision from The U.N. to reclassify cannabis as a less dangerous drug

Highlights after the period

- February 2021, STENOCARE announced the first delivery of THC-CBD balanced medical cannabis oil products to Swedish patients

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com

This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on February 25, 2021.

STENOCARE’s Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: info@keswickglobal.com

About STENOCARE A/S

STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency’s permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.

www.stenocare.dk

www.stenocare.se

www.stenocare.com